{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:48:21Z","timestamp":1782978501467,"version":"3.54.5"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Kidney Health Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While sodium-glucose cotransporter-2 (SGLT2) inhibitors provide major benefits across multiple chronic diseases, clinician prescription and patient adherence rates remain low.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore perspectives of clinician and patient stakeholders regarding barriers and facilitators for SGLT2 inhibitor use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Semi-structured interviews, conducted as part of a larger project examining the type 2 diabetes mellitus (T2DM) standard of care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Australia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Clinicians involved in the care of people with T2DM, including primary care clinicians, endocrinologists, nephrologists, cardiologists, diabetes educators, and pharmacists; and adults with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Barriers and facilitators of SGLT2 inhibitor implementation were explored through the Consolidated Framework for Implementation Research. Analysis of interview transcripts was conducted in duplicate using a combination of framework and thematic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 24 clinicians, and four people with T2DM, were interviewed between November 2021 and August 2023, including four primary care clinicians, four endocrinologists, four nephrologists, four cardiologists, four diabetes educators, and four pharmacists. Key findings included that clinicians miss opportunities to prescribe due to competing priorities and therapeutic inertia, and may find it difficult to educate and engage patients about SGLT2 inhibitor use. Patients require detailed education to understand benefits and adverse effect prevention, ideally with multimodal resources and staggered over time, and would benefit from general adherence coaching. Some clinicians were concerned about the risk of urinary tract infections despite reassuring safety data, and few provided genital hygiene advice to reduce SGLT2 inhibitor-associated genital mycotic infections. Better health system support could be achieved through additional cost reimbursement and support for multidisciplinary care access.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitations<\/jats:title>\n                    <jats:p>Most participants were from a single Australian state, New South Wales, which may not fully reflect experiences across Australia. Participation bias may under-represent those less engaged in SGLT2 inhibitor use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians are convinced about SGLT2 inhibitor benefits but require support to deliver evidence-based care, including effective patient education and engagement. These insights can help inform the design of interventions to maximise societal benefit from these effective medications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20543581261463450","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T11:57:34Z","timestamp":1782734254000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers and Facilitators for Sodium-Glucose Cotransporter-2 Inhibitor Uptake and Implementation in Australia \u2013 Perspectives From Clinicians and Patients: An Interview Study"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6066-8860","authenticated-orcid":false,"given":"Daniel V.","family":"O\u2019Hara","sequence":"first","affiliation":[{"name":"University of Sydney"},{"name":"Department of Renal Medicine, Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-1170","authenticated-orcid":false,"given":"Tae Won","family":"Yi","sequence":"additional","affiliation":[{"name":"University of Sydney"},{"name":"University Health Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg J.","family":"Jardine","sequence":"additional","affiliation":[{"name":"University of Sydney"},{"name":"Department of Renal Medicine, Concord Repatriation General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael L","family":"Morton","sequence":"additional","affiliation":[{"name":"University of Sydney"},{"name":"The University of Sydney"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-024-00836-y"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2023.100988"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3350"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/20543581231217857"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"e_1_3_9_7_2","volume-title":"Dapagliflozin for chronic kidney disease [Internet]","author":"NPS MedicineWise","year":"2022","unstructured":"NPS MedicineWise. Dapagliflozin for chronic kidney disease [Internet]. Sydney: NPS MedicineWise; 2022. [cited 2024 Jun 7]. Available from: https:\/\/www.safetyandquality.gov.au\/medicine-finder\/forxiga-tablets"},{"key":"e_1_3_9_8_2","volume-title":"Australian Government Department of Health and Aged Care: Pharmaceutical Benefits Scheme","unstructured":"Australian Government Department of Health and Aged Care: Pharmaceutical Benefits Scheme. Dapagliflozin [Internet]. Canberra: Australian Government Department of Health and Aged Care; [cited 2024 Jun 7]. Available from: https:\/\/www.pbs.gov.au\/"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-4-50"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_3_9_12_2","volume-title":"SGLT2 Inhibitors [Internet]","author":"European Medicines Agency","year":"2016","unstructured":"European Medicines Agency. SGLT2 Inhibitors [Internet]. European Medicines Agency; 2016. [cited 2023 Dec 12]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/sglt2-inhibitors."},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0310057x1804600202"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.11.002"},{"key":"e_1_3_9_15_2","volume-title":"Optimization of SGLT2i therapy toolkit [Internet]","unstructured":"Optimization of SGLT2i therapy toolkit [Internet]. Belgium: International Society of Nephrology; [cited 2025 Jun 19]. Available from: https:\/\/www.theisn.org\/initiatives\/toolkits\/sglt2i-toolkit\/#Patients"},{"key":"e_1_3_9_16_2","unstructured":"NSW Therapeutic Advisory Group Inc. Consumer information leaflet: SGLT2 inhibitor medicines for diabetes (Version 2). Sydney: NSW TAG: Diabetes Service Rural Support Service; 2024. https:\/\/www.nswtag.org.au\/wp-content\/uploads\/2024\/04\/Consumer-Information-Leaflet_SGLT2i-Medicines-for-Diabetes_V2_3Apr2024_.pdf"},{"key":"e_1_3_9_17_2","volume-title":"Three things you need to know about SGLT2 inhibitors [Internet]","author":"Diabetes Australia","year":"2022","unstructured":"Diabetes Australia. Three things you need to know about SGLT2 inhibitors [Internet]. Diabetes Australia; 2022. [cited 2024 Jun 7]. Available from: https:\/\/www.diabetesaustralia.com.au\/blog\/sglt2-inhibitors\/."},{"key":"e_1_3_9_18_2","volume-title":"Clinical Guidelines [Internet]","author":"Australian Diabetes Society","unstructured":"Australian Diabetes Society. Clinical Guidelines [Internet]. Sydney: Australian Diabetes Society. [cited 2024 Mar 14]. Available from: https:\/\/www.diabetessociety.com.au\/guideline\/"},{"key":"e_1_3_9_19_2","volume-title":"Management of type 2 diabetes: A handbook for general practice","author":"The Royal Australian College of General Practitioners","year":"2020","unstructured":"The Royal Australian College of General Practitioners. Management of type 2 diabetes: A handbook for general practice. East Melbourne, Vic: RACGP; 2020."},{"key":"e_1_3_9_20_2","volume-title":"Living Evidence Guidelines in Diabetes [Internet]","author":"Living Evidence for Diabetes Consortium","year":"2024","unstructured":"Living Evidence for Diabetes Consortium. Living Evidence Guidelines in Diabetes [Internet]. Australian Diabetes Society; 2024. [cited 2024 Apr 26]. Available from: https:\/\/www.diabetessociety.com.au\/living-evidence-guidelines-in-diabetes\/"},{"key":"e_1_3_9_21_2","volume-title":"Australian Government Department of Health and Aged Care: Pharmaceutical Benefits Scheme","unstructured":"Australian Government Department of Health and Aged Care: Pharmaceutical Benefits Scheme. Empagliflozin [Internet]. Canberra: Australian Government Department of Health and Aged Care; [cited 2025 Mar 18]. Available from: https:\/\/www.pbs.gov.au\/"},{"key":"e_1_3_9_22_2","volume-title":"Unlocking hope for people with kidney disease [Internet]","author":"University of New South Wales","year":"2023","unstructured":"University of New South Wales. Unlocking hope for people with kidney disease [Internet]. Sydney: University of New South Wales; 2023. [cited 2024 Jun 7]. Available from: https:\/\/www.unsw.edu.au\/newsroom\/news\/2023\/03\/unlocking-hope-for-people-with-kidney-disease-#:\u223c:text=SGLT2inhibitorsareavailablein,PharmaceuticalBenefitsScheme(PBS)."},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01798-4"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/medlaw\/fwae015"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02733-w"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020951928"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","unstructured":"Williams S Ahmed S. 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice. Diabetes. 2019;68. doi:10.2337\/db19-1224-P.","DOI":"10.2337\/db19-1224-P"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-7625.2007.00454.x"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15597"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109036"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16203"}],"container-title":["Canadian Journal of Kidney Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581261463450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20543581261463450","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20543581261463450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:19:53Z","timestamp":1782976793000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20543581261463450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["10.1177\/20543581261463450"],"URL":"https:\/\/doi.org\/10.1177\/20543581261463450","relation":{},"ISSN":["2054-3581","2054-3581"],"issn-type":[{"value":"2054-3581","type":"print"},{"value":"2054-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"20543581261463450"}}